Equities analysts expect that DURECT Co. (NASDAQ:DRRX) will report earnings of ($0.05) per share for the current quarter, according to Zacks. Three analysts have issued estimates for DURECT’s earnings. The lowest EPS estimate is ($0.05) and the highest is ($0.04). DURECT posted earnings per share of ($0.04) during the same quarter last year, which would indicate a negative year over year growth rate of 25%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 7th.
On average, analysts expect that DURECT will report full-year earnings of ($0.20) per share for the current financial year, with EPS estimates ranging from ($0.21) to ($0.18). For the next financial year, analysts expect that the company will report earnings of ($0.19) per share, with EPS estimates ranging from ($0.22) to ($0.16). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for DURECT.
DURECT (NASDAQ:DRRX) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. DURECT had a negative return on equity of 108.92% and a negative net margin of 125.76%. The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $3.50 million.
Separately, HC Wainwright reissued a “buy” rating on shares of DURECT in a research report on Thursday, April 18th.
In other DURECT news, Director Jon S. Saxe acquired 40,400 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $0.70 per share, with a total value of $28,280.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have purchased a total of 71,700 shares of company stock valued at $53,746 over the last three months. Corporate insiders own 10.20% of the company’s stock.
Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its position in shares of DURECT by 1,420.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 42,545 shares of the specialty pharmaceutical company’s stock worth $27,000 after purchasing an additional 39,746 shares during the last quarter. Virtu Financial LLC purchased a new position in DURECT during the 4th quarter valued at about $32,000. Prudential Financial Inc. boosted its holdings in DURECT by 541.8% during the 4th quarter. Prudential Financial Inc. now owns 89,460 shares of the specialty pharmaceutical company’s stock valued at $43,000 after acquiring an additional 75,520 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in DURECT by 22.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 100,123 shares of the specialty pharmaceutical company’s stock valued at $62,000 after acquiring an additional 18,478 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in DURECT by 787.0% during the 4th quarter. SG Americas Securities LLC now owns 140,745 shares of the specialty pharmaceutical company’s stock valued at $68,000 after acquiring an additional 124,878 shares during the period. 45.71% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:DRRX traded up $0.01 during midday trading on Friday, reaching $0.68. 4,857 shares of the company’s stock were exchanged, compared to its average volume of 874,712. The company has a current ratio of 3.74, a quick ratio of 3.39 and a debt-to-equity ratio of 1.82. The company has a market capitalization of $108.80 million, a price-to-earnings ratio of -4.16 and a beta of 2.02. DURECT has a fifty-two week low of $0.46 and a fifty-two week high of $2.25.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
See Also: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.